Host defense molecule polymorphisms influence the risk for immune- mediated complications in chronic granulomatous disease

Journal of Clinical Investigation

Volumn 102, Issue 12, 1998, Pages 2146-2155

  Foster, Charles B ^a   Lehrnbecher, Thomas ^a   Mol, Femke ^a   Steinberg, Seth M ^b   Venzon, David J ^b   Walsh, Thomas J ^a   Noack, Deborah ^c   Rae, Julie ^d   Winkelstein, Jerry A ^e   Curnutte, John T ^d,f   Chanock, Stephen J ^a,b  

^a Pediatric Oncology Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d GENENTECH INC   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fc receptor; Gastric outlet obstruction; Mannose binding lectin; Myeloperoxidase; Rheumatological disorders

Indexed keywords

FC RECEPTOR;

ADOLESCENT; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; CHILD; CHRONIC GRANULOMATOUS DISEASE; GASTROINTESTINAL DISEASE; GENETIC POLYMORPHISM; HOST RESISTANCE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0032535301     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5084     Document Type: Article

References (12)

1. Curnutte, J.T. 1993. Chronic granulomatous disease: the solving of a clinical riddle at the molecular level. Clin. Immnnol. Immunopathol. 67:S2-S15.
2. Babior, B.M., J. el Benna, S.J. Chanock, and R.M. Smith. 1997. The NADPH oxidase of leukocytes: the respiratory burst oxidase. In Oxidative Stress and the Molecular Biology of Antioxidant Defenses. J.G. Scandalios, editor. Cold Spring Harbor Laboratory Press, Plainview, NY. 737-783.
3. Segal, A.W. 1996. The NADPH oxidase and chronic granulomatous disease. Mol. Med. Today. 2:129-135.
4. Thrasher, A.J., N.H. Keep, F. Wientjes, and A.W. Segal. 1994. Chronic granulomatous disease. Biochim. Biophys. Acta. 1227:1-24.
5. Gallin, J.I., E.S. Buescher, B.E. Seligmann, J. Nath, T. Gaither, and P. Katz. 1983. NIH conference. Recent advances in chronic granulomatous disease. Ann. Intern. Med. 99:657-674.
6. Rosh, J.R., H.B. Tang, L. Mayer, G. Groisman, S.K. Abraham, and A. Prince. 1995. Treatment of intractable gastrointestinal manifestations of chronic granulomatous disease with cyclosporine. J. Pediatr. 126:143-145.
7. Danziger, R.N., A.T. Goren, J. Becker, J.M. Greene, and S.D. Douglas. 1993. Outpatient management with oral corticosteroid therapy for obstructive conditions in chronic granulomatous disease. J. Pediatr. 122:303-305.
8. Aliabadi, H., R. Gonzalez, and P.G. Quie. 1989. Urinary tract disorders in patients with chronic granulomatous disease. N. Engl. J. Med. 321:706-708.
9. Chin, T.W., E.R. Stiehm, J. Falloon, and J.I. Gallin. 1987. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease. J. Pediatr, 111:349-352.
10. Werlin, S.L., M.J. Chusid, J. Caya, and H.W. Oechler. 1982. Colitis in chronic granulomatous disease. Gastroenterology. 82:328-331.
11. Varma, V.A., J.T. Sessions, L.B. Kahn, and S. Lipper. 1982. Chronic granulomatous disease of childhood presenting as gastric outlet obstruction. Am. J. Surg. Pathol. 6:673-676.
12. Schmitt, C.P., K. Scharer, R. Waldherr, R.A. Seger, and K.M. Debatin. 1995. Glomerulonephritis associated with chronic granulomatous disease and systemic lupus erythematosus. Nephrol. Dial. Transplant. 10:891-895.